Indication
Wolfram Syndrome
5 clinical trials
5 products
Clinical trial
A Phase II Study of Safety and Efficacy of AMX0035 in Adult Patients With Wolfram SyndromeStatus: Active (not recruiting), Estimated PCD: 2024-07-17
Product
AMX0035Clinical trial
Towards a Personalized Precision Medicine in Rare Disease: Tirzepatide (a Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 Receptor Agonist) Monotherapy in Patients With Wolfram Syndrome Type 1Status: Recruiting, Estimated PCD: 2024-10-01
Product
TirzepatideClinical trial
A Phase 1b/2a Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram SyndromeStatus: Completed, Estimated PCD: 2023-02-01
Product
DantroleneClinical trial
AUDIOWOLF: A Phase II, Open-label, Efficacy Study of Daily Administration of Sodium Valproate in Patients Clinically Affected by Wolfram Syndrome Due to Monogenic Mutation.Status: Recruiting, Estimated PCD: 2025-11-01
Product
DepakineClinical trial
A Pivotal, International, Randomised, Double-blind, Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram SyndromeStatus: Active (not recruiting), Estimated PCD: 2024-11-15
Product
Sodium Valproate